Mrs. Jelena Kovacic | New Drug Development | Best Researcher Award

Posted on by Pencis

Mrs. Jelena Kovacic | New Drug Development | Best Researcher Award

Faculty of Pharmacy and Biochemistry University of Zagreb | Croatia

Author Profile

Scopus

ORCID ID

Google Scholar

🎓EARLY ACADEMIC PURSUITS 

Jelena Kovačić embarked on her academic journey with a Master of Science in Applied Chemistry from the Faculty of Chemical Engineering and Technology in Zagreb, completed in 2021. Her master’s thesis focused on the monitoring of degradation of selected active substances, laying a solid foundation for her research career.

🔬PROFESSIONAL ENDEAVORS 

Jelena is currently a Ph.D. researcher at the Faculty of Pharmacy and Biochemistry, University of Zagreb. Her work primarily involves developing advanced analytical methods for drugs and biologically active substances, specifically targeting treatments for inflammatory bowel disease. Her role also includes involvement in stability-indicative methods, compatibility studies, and therapeutic drug monitoring.

🧪CONTRIBUTIONS AND RESEARCH FOCUS 

Jelena’s research contributions are centered around preformulation studies, including forced degradation studies and compatibility assessments. She is also engaged in bioanalytical research, focusing on therapeutic drug monitoring and microextraction techniques. Her work involves advanced analytical techniques such as liquid chromatography (LC), mass spectrometry (MS), and chemometrics.

🌟IMPACT AND INFLUENCE 

Through her active participation in international symposia and congresses, Jelena has contributed to the broader scientific community’s understanding of analytical methods and bioanalytical techniques. Her research aims to enhance the efficacy and safety of drug treatments, particularly in the context of inflammatory bowel diseases.

📚ACADEMIC CITATIONS 

Jelena has established a growing presence in the academic community with her research contributions and presentations at various international platforms. Her work is expected to garner more citations as she progresses in her doctoral studies and publishes her findings.

🔮LEGACY AND FUTURE CONTRIBUTIONS 

Jelena Kovačić’s future contributions are anticipated to make a significant impact on the field of pharmaceutical sciences. With her expertise in developing advanced analytical methods and her dedication to research in drug treatments, she is poised to advance the understanding and application of these methods in clinical settings, thereby shaping future research and development in the field.

🎯Conclusion

Jelena Kovačić is an emerging researcher with a strong foundation in applied chemistry and a promising trajectory in pharmaceutical sciences. Her academic pursuits and professional experiences reflect a deep commitment to advancing analytical methods and bioanalytical techniques, particularly in the treatment of inflammatory bowel disease. Through her work, she contributes valuable insights into drug development and stability, enhancing the field’s overall knowledge and application. Her active participation in international forums and her ongoing research efforts position her as a future leader in pharmaceutical research, with the potential to significantly influence drug treatment methodologies and improve patient outcomes. As she continues to develop her expertise, Jelena is set to leave a lasting impact on the scientific community

📊🔬NOTABLE PUBLICATION:

 

  • Polyphenol content and antioxidant activity of phytoestrogen containing food and dietary supplements: DPPH free radical scavenging activity by HPLC
    • Authors: Klarić, D.A., Mornar, A., Kovačić, J., Brletić, I., Klarić, I.
    • Journal: Acta Pharmaceutica
    • Year: 2022

 

  • Accessing Lipophilicity and Biomimetic Chromatography Profile of Biologically Active Ingredients of Botanicals Used in the Treatment of Inflammatory Bowel Disease
    • Authors: Jeličić, M.-L., Amidžić Klarić, D., Kovačić, J., Verbanac, D., Mornar, A.
    • Journal: Pharmaceuticals
    • Year: 2022

 

  • Green Solid-Phase (Micro)Extraction of Andrographolides from Human Plasma Samples Followed by UHPLC-DAD-QqQ-MS/MS Analysis
    • Authors: Kovačić, J., Jeličić, M.-L., Amidžić Klarić, D., Mornar, A.
    • Journal: Separations
    • Year: 2023

 

  • Antioxidant Activity of Pharmaceuticals: Predictive QSAR Modeling for Potential Therapeutic Strategy
    • Authors: Jeličić, M.-L., Kovačić, J., Cvetnić, M., Mornar, A., Klarić, D.A.
    • Journal: Pharmaceuticals
    • Year: 2022

 

  • Size exclusion chromatography as green support for forced degradation study of adalimumab
    • Authors: Kovačić, J., Klarić, D.A., Turk, N., Mornar, A.
    • Journal: Acta Pharmaceutica
    • Year: 2023

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

📊🔬Notable Publication:

 

 

 

 

Drug Design and Clinical Trials

Posted on by Pencis

Drug Design and Clinical Trials

 

Introduction: Drug Design and Clinical Trials

The field of drug design and clinical trials represents a crucial bridge between scientific innovation and the improvement of human health. It encompasses the intricate processes involved in developing new pharmaceutical agents, assessing their safety and efficacy, and ultimately bringing them to the patients who need them. This dynamic and collaborative field plays a pivotal role in advancing medical treatments and therapeutics for a wide range of diseases and conditions.

Subtopics:

Rational Drug Design: Rational drug design involves the targeted creation of new drugs based on a deep understanding of the biological mechanisms underlying diseases. This subtopic explores the principles and techniques used in designing drugs with enhanced specificity and effectiveness.

Preclinical Testing: Before advancing to human trials, potential drug candidates undergo rigorous preclinical testing. This subtopic discusses the various stages of preclinical testing, including in vitro and animal studies, to evaluate safety and efficacy.

Clinical Trial Phases: Clinical trials are divided into phases, each serving a distinct purpose. This subtopic outlines the different phases (Phase I, II, III, and IV) of clinical trials, highlighting their objectives and the types of participants involved.

Patient Recruitment and Informed Consent: The recruitment of participants and obtaining informed consent are critical ethical aspects of clinical trials. This subtopic explores the importance of ethical considerations, participant rights, and the informed consent process in clinical research.

Data Analysis and Regulatory Approval: After the completion of clinical trials, data analysis and regulatory approval processes determine the fate of a drug candidate. This subtopic delves into the statistical methodologies used to analyze trial data and the regulatory agencies responsible for approving new drugs for market release.